NRX Pharmaceuticals vs Xenetic Biosciences
Xenetic Biosciences is the larger business, with $3.0m of revenue in fiscal 2025 against $1.2m for NRX Pharmaceuticals (2.4 times as much). Xenetic Biosciences kept more of each dollar of sales as profit: a net margin of -90.1% against -2336.5%.
| Latest fiscal year | NRX PharmaceuticalsNRXP, 2025 | Xenetic BiosciencesXBIO, 2025 |
|---|---|---|
| Revenue | $1.2m | $3.0m |
| Revenue growth | — | 19.0% |
| Net income | −$28.6m | −$2.7m |
| Operating margin | — | — |
| Net margin | -2336.5% | -90.1% |
| Return on equity | — | -40.0% |
| Free cash flow | −$14.1m | −$2.3m |
| Cash | $7.8m | $7.9m |
| Total debt | $0 | $0 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 29 | — |
| Market value | $100m | $5.0m |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |